Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.
Mira JA, López-Cortés LF, Barreiro P, Tural C, Torres-Tortosa M, de Los Santos Gil I, Martín-Rico P, Ríos-Villegas MJ, Hernández-Burruezo JJ, Merino D, López-Ruz MA, Rivero A, Muñoz L, González-Serrano M, Collado A, Macías J, Viciana P, Soriano V, Pineda JA. Mira JA, et al. J Antimicrob Chemother. 2008 Dec;62(6):1365-73. doi: 10.1093/jac/dkn420. Epub 2008 Oct 13. J Antimicrob Chemother. 2008. PMID: 18854330 Clinical Trial.
Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy.
Pineda JA, García-García JA, Aguilar-Guisado M, Ríos-Villegas MJ, Ruiz-Morales J, Rivero A, del Valle J, Luque R, Rodríguez-Baño J, González-Serrano M, Camacho A, Macías J, Grilo I, Gómez-Mateos JM; Grupo para el Estudio de las Hepatitis Víricas de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Pineda JA, et al. Hepatology. 2007 Sep;46(3):622-30. doi: 10.1002/hep.21757. Hepatology. 2007. PMID: 17659577
Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
Pineda JA, Mira JA, Gil Ide L, Valera-Bestard B, Rivero A, Merino D, Girón-González JA, Ríos-Villegas MJ, González-Serrano M, Collado A, García-García JA, Carrillo-Gómez R, López-Cortés LF, Gómez-Mateos J. Pineda JA, et al. J Antimicrob Chemother. 2007 Dec;60(6):1347-54. doi: 10.1093/jac/dkm373. Epub 2007 Oct 14. J Antimicrob Chemother. 2007. PMID: 17938129
Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.
Mira JA, López-Cortés LF, Merino D, Arizcorreta-Yarza A, Rivero A, Collado A, Ríos-Villegas MJ, González-Serrano M, Torres-Tortoso M, Macías J, Valera-Bestard B, Fernández-Fuertes E, Girón-González JA, Lozano F, Pineda JA; Grupo para el Estudio de las Hepatitis Viricas de la Sociedad Andaluza de Enfermedades Infecciosas. Mira JA, et al. Antivir Ther. 2007;12(8):1225-35. Antivir Ther. 2007. PMID: 18240862
Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.
Crespo M, Mira JA, Pineda JA, Van den Eynde E, Ríos-Villegas MJ, Collado A, Girón-González JA, López-Cortés LF, González-Serrano M, Rivero A, Merino D, Esteban JI. Crespo M, et al. J Antimicrob Chemother. 2008 Oct;62(4):793-6. doi: 10.1093/jac/dkn262. Epub 2008 Jun 21. J Antimicrob Chemother. 2008. PMID: 18567911
Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients.
Pineda JA, Aguilar-Guisado M, Rivero A, Girón-González JA, Ruiz-Morales J, Merino D, Ríos-Villegas MJ, Macías J, López-Cortés LF, Camacho A, Merchante N, Del Valle J; Grupo para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas. Pineda JA, et al. Clin Infect Dis. 2009 Oct 15;49(8):1274-82. doi: 10.1086/605676. Clin Infect Dis. 2009. PMID: 19772387
Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression.
Mira JA, Gutiérrez-Valencia A, Gil Ide L, Merino D, Rivero A, Ríos-Villegas MJ, Delgado M, González-Serrano M, Collado A, Torres-Tortosa M, Omar M, López-Ruz MA, Macías J, Arponen S, Pineda JA. Mira JA, et al. Clin Infect Dis. 2009 Oct 15;49(8):e84-91. doi: 10.1086/605677. Clin Infect Dis. 2009. PMID: 19772388
Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients.
Merchante N, López-Cortés LF, Delgado-Fernández M, Ríos-Villegas MJ, Márquez-Solero M, Merino D, Pasquau J, García-Figueras C, Martínez-Pérez MA, Omar M, Rivero A, Macías J, Mata R, Pineda JA; Grupo Andaluz para el Estudio de las Hepatitis Vıricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Merchante N, et al. AIDS Patient Care STDS. 2011 Jul;25(7):395-402. doi: 10.1089/apc.2011.0109. Epub 2011 Jun 20. AIDS Patient Care STDS. 2011. PMID: 21688986 Clinical Trial.
Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients.
Mira JA, Rivero A, de Los Santos-Gil I, López-Cortés LF, Girón-González JA, Márquez M, Merino D, del Mar Viloria M, Téllez F, Ríos-Villegas MJ, Omar M, Rivero-Juárez A, Macías J, Pineda JA; Grupo HEPAVIR de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Mira JA, et al. AIDS. 2012 Aug 24;26(13):1721-4. doi: 10.1097/QAD.0b013e3283568884. AIDS. 2012. PMID: 22695304
45 results